- Trials with a EudraCT protocol (518)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
518 result(s) found for: Skin biopsy.
Displaying page 1 of 26.
EudraCT Number: 2017-003495-31 | Sponsor Protocol Number: CCLL442X2201 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w... | |||||||||||||
Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001722-21 | Sponsor Protocol Number: D533AC00001 | Start Date*: 2022-03-08 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance ... | ||||||||||||||||||
Medical condition: Unresectable or Advanced Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003765-10 | Sponsor Protocol Number: I-Tackle | Start Date*: 2018-07-10 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance | |||||||||||||
Medical condition: Patient with Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002790-35 | Sponsor Protocol Number: C12-48 | Start Date*: 2019-06-04 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector | |||||||||||||
Medical condition: The trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005332-30 | Sponsor Protocol Number: ACT16845 | Start Date*: 2021-09-27 | ||||||||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT | ||||||||||||||||||
Full Title: A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with adva... | ||||||||||||||||||
Medical condition: Advanced unresectable or metastatic skin cancers | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003601-10 | Sponsor Protocol Number: NL69300 | Start Date*: 2020-09-18 | |||||||||||
Sponsor Name:Amsterdam University Medical Centers | |||||||||||||
Full Title: Treatment of Skin Severity in Ichthyosis with Hyperbaric Oxygen Therapy | |||||||||||||
Medical condition: ichthyosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003802-14 | Sponsor Protocol Number: CRC-PSO-SKINPEN-A-27 | Start Date*: 2016-11-25 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients | |||||||||||||
Medical condition: Psoriasis vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003921-51 | Sponsor Protocol Number: BOT112-03 | Start Date*: 2021-02-11 | |||||||||||
Sponsor Name:Highlight Therapeutics | |||||||||||||
Full Title: Phase 2 single arm clinical study to evaluate the efficacy and safety of intratumoral administration of BO-112 in combination with pembrolizumab in subjects that have progressed on anti-PD-1-based ... | |||||||||||||
Medical condition: Advanced melanoma after progression to immunotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002276-13 | Sponsor Protocol Number: CA209-7DL | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:University Hospital Essen, Department of Dermatology | |||||||||||||
Full Title: Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification | |||||||||||||
Medical condition: Stage II melanoma arising from a primary cutaneous site after surgery therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000331-41 | Sponsor Protocol Number: CHDR1430 | Start Date*: 2016-03-22 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers | |||||||||||||
Medical condition: none, this is a study on healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003123-37 | Sponsor Protocol Number: | Start Date*: 2006-10-12 |
Sponsor Name:University Hospital Sint Radboud | ||
Full Title: Treatment with high dose Methotrexate in patients with eosinophilic fasciitis | ||
Medical condition: Eosinophilic fasciitis (EF) is a skin disorder involving the deep fascia, resulting in pain and swelling of extremities, cutaneous induration and joint contractures. Most patients require therapy. ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003262-12 | Sponsor Protocol Number: PO-001 | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Pega-One S.A.S. | |||||||||||||
Full Title: Phase 2 study of Imgatuzumab in patients with advanced cutaneous squamous cell carcinoma (I-PACE) | |||||||||||||
Medical condition: advanced cutaneous squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002464-24 | Sponsor Protocol Number: ESA-13/2010 | Start Date*: 2011-07-15 |
Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel | ||
Full Title: Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with dermatoporosis | ||
Medical condition: dermatoporosis stage I and II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002669-37 | Sponsor Protocol Number: EMR200066-007 | Start Date*: 2013-02-20 | |||||||||||
Sponsor Name:Merck Serono S.A. Geneva | |||||||||||||
Full Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cuta... | |||||||||||||
Medical condition: N-RAS mutated locally advanced or metastatic malignant cutaneous melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002076-28 | Sponsor Protocol Number: P151202 | Start Date*: 2016-08-23 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients with unresectable Squamous Cell Carcinoma of the Skin | |||||||||||||
Medical condition: Patients with unresectable Squamous Cell Carcinoma of the Skin will be included. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005569-10 | Sponsor Protocol Number: Bottom_2012 | Start Date*: 2013-08-19 | ||||||||||||||||||||||||||
Sponsor Name:University Hospital Essen | ||||||||||||||||||||||||||||
Full Title: Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastati... | ||||||||||||||||||||||||||||
Medical condition: Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600 mutation-positive | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005628-41 | Sponsor Protocol Number: TR03ext | Start Date*: 2015-02-06 | |||||||||||
Sponsor Name:Trevi Therapeutics, Inc. | |||||||||||||
Full Title: An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients | |||||||||||||
Medical condition: Prurigo Nodularis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000141-39 | Sponsor Protocol Number: 110118 | Start Date*: 2018-03-08 | |||||||||||
Sponsor Name:Merete Hædersdal | |||||||||||||
Full Title: Tolerabililty of laser-assisted cisplatin+5-fluorouracil― an exploratory proof of concept study of topical combination chemotherapy for basal cell carcinoma | |||||||||||||
Medical condition: Patients over 18 years of age with a previously untreated superficial or nodular basal cell carcinoma (BCC) on the scalp, face, extremities or trunk | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003884-20 | Sponsor Protocol Number: MK-1986-018 | Start Date*: 2017-06-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects 3 Months to <12 Years of Age with A... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA DE (Completed) PL (Completed) BG (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002069-30 | Sponsor Protocol Number: 13069 | Start Date*: 2008-12-05 |
Sponsor Name:Bayer Vital GmbH | ||
Full Title: A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by inv... | ||
Medical condition: Biopsy wounds on healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
